| Literature DB >> 3124609 |
R D Gordon1, A G Tzakis, S Iwatsuki, S Todo, C O Esquivel, J W Marsh, A Stieber, L Makowka, T E Starzl.
Abstract
Experience with the use of Orthoclone OKT3 monoclonal antibody for the treatment of acute cellular rejection in a series of 130 human orthotopic liver transplantations is reviewed. Treatment was highly effective in reversing rejection, in reducing the rate of retransplantation, and in lowering patient mortality. OKT3 was also useful for cyclosporine sparing in patients with poor renal function, hypertension, or CNS toxicity. There was a significant incidence of opportunistic infection associated with the use of OKT3.Entities:
Mesh：
Substances：
Year: 1988 PMID： 3124609 PMCID： PMC2958668 DOI： 10.1016/s0272-6386(88)80199-9
Source DB: PubMed Journal: Am J Kidney Dis ISSN： 0272-6386 Impact factor: 8.860